European Psychiatry - Volume 41 - April 2017

373 / 916

25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404 S369
Long-acting injectables (LAIs) could be a safe option to guarantee
the efficacy.
Aim and objectives Our purpose is to evaluate the efficacy of the
switch to paliperidone palmitate from other oral or LAI antipsy-
chotics, in terms of hospital and emergency admissions.
Methods We performed a mirror-image study in an outpatient
mental health clinic, comparing patients before and after paliperi-
done palmitate change over 43 months. Fifty-seven patients were
included, most of them (n = 47) were diagnosed with psychotic
disorders (82.5%) while 4 were bipolar patients (7%), and the
remained patients (n = 6; 10.6%) were classified as behavioral dis-
orders. The following variables were studied before and after the
switching: number of admissions, days of stay and emergency
visits.
Results From those 57 patients, 44 were previously treated with
other LAIs, whereas 13 were taking oral antipsychotics. Themedian
age at switch was 49 years (SD = 12.31). The reasons for switch-
ing were: inefficacy (26.3%), non-adherence (19.3%), side effects
(38.6%), and non-specified (15.8%).We found significant differences
between the three main variables: number of admissions (t = 4.59;
P ≤ 0.001), days of stay ( t = 2.27; P = 0.027) and emergency visits
(t = 3.74; P ≤ 0.001).
Conclusions Paliperidone palmitate seems to be an effective
treatment in order to guarantee the adherence. Our preliminary
data show that paliperidone palmitate might reduce the sanitary
cost in outpatients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0762
Web search query data and
prescription volumes of
antidepressants
M. Gahr ∗ zelac eiss . Connemann Lang
C. Schönfeldt-Lecuona
1 University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm,
Germany
2 University Hospital of Ulm, Psychosomatic Medicine and
Psychotherapy, Ulm, Germany
∗ Corresponding author.
Introduction Persons using the Internet generate large amounts
of health-related data, which are increasingly used in modern
health sciences.
Objectives/aims We analysed the relation between annual pre-
scription volumes (APV) of several antidepressants with marketing
approval in Germany and corresponding web search query data
generated in Google to test, if web search query volume may be a
proxy for medical prescription practice.
Methods We obtained APVs of several antidepressants related
to corresponding prescriptions at the expense of the statu-
tory health insurance in Germany from 2004–2013. Web search
query data generated in Germany and related to defined search-
terms (active substance or brand name) were obtained with
Google Trends. We calculated correlations (Pearson’s r) between
the APVs of each substance and the respective annual “search
share” values; coefficients of determination (R2) were com-
puted to determine the amount of variability shared by the two
variables.
Results Significant and strong correlations between substance-
specific APVs and corresponding annual query volume were found
for each substance during the observational interval: agomela-
tine (r= 0.968; R2 = 0.932; P = 0.01), bupropion (r= 0.962; R2 = 0.925;
P = 0.01), citalopram (r = 0.970; R2 = 0.941; P = 0.01), escitalopram
(r = 0.824; R2 = 0.682; P = 0.01), fluoxetine (r = 0.885; R2 = 0.783;
P = 0.01), paroxetine (r= 0.801; R2 = 0.641; P = 0.01), and sertraline
(r = 0.880; R2 = 0.689; P = 0.01).
Conclusions Although the used data did not allow to perform
an analysis with a higher temporal resolution our results suggest
that web search query volume may be a proxy for correspond-
ing prescription behaviour. However, further studies analysing
other pharmacologic agents and prescription data that facilitates an
increased temporal resolution are needed to confirm this hypoth-
esis.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0763
Underreporting of adverse drug
reactions: Results from a survey
among physicians
M. Gahr∗, J. Eller , B.J. Connemann , C. Schönfeldt-Lecuona
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm,
Germany
∗ Corresponding author.
Introduction Drug safety surveillance strongly depends on the
spontaneous and voluntary reporting of adverse drug reactions
(ADR). A major limiting factor of spontaneous reporting systems
is underreporting (UR) which describes incorrectly low reporting
rates of ADR. Factors contributing to UR are numerous and feature
country-dependent differences.
Objectives/aims Understanding causes of UR is necessary to
facilitate targeted interventions to improve ADR reporting and
pharmacovigilance.
Methods A cross-sectional questionnaire-based telephone sur-
veywas performed among physicians in outpatient care in a federal
state of Germany.
Results From n = 316 eligible physicians n = 176 completed
the questionnaire (response rate = 55.7%). Most of the physi-
cians (n = 137/77.8%) stated that they report ADR, which they
have observed to the competent authority rarely (n = 59/33.5%),
very rarely (n = 59/33.5%) or never (n = 19/10.8%); the majority
(n = 123/69.9%) had not reported any ADR in 2014. Frequent sub-
jective reasons for ADR non-reporting were (specified response
options): lack of time (n = 52/29.5%), the subjective evaluation that
the required process of reporting is complicated (n = 47/26.7%)
or requires too much time (n = 25/14.2%) or the assessment that
reporting of an ADR is needless (n = 22/12.5%); within free answers
the participants frequently stated that they do not report ADR that
are already known (n = 72/40.9%) and they only report severe ADR
(n = 46/26.1%).
Conclusions Our results suggest a need of interventions to inform
physicians about pharmacovigilance and to modify the required
procedure of ADR reporting or to offer other reporting options.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0764
Treatment attitude and
hospitalization: Comparison of oral
therapy and long-acting injectable
(LAI) antipsychotics in patients with
schizophrenia
L. Montemagno∗, M. Ludovico , A. Distefano , M. Marta Valentina ,
B. Mariacatena , C. Maria , M. Antonio , P. Antonino
University of Catania, Department of Clinical and Experimental
Medicine, Catania, Italy
∗ Corresponding author.
Background Adherence to prescribed antipsychotic drugs is a
crucial factor in predicting medium- to long-term clinical out-